

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																							
<p>Salengros et al. 2010</p> <p>Different anaesthetic techniques associated with different incidences of chronic post-thoracotomy pain: low-dose remifentanyl plus presurgical epidural analgesia is preferable to high-dose remifentanyl with postsurgical epidural analgesia.</p> <p>J Cardiothorac Vasc Anesth. 2010;24(4):608-16.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - not reported <p>exclusion criteria</p> <ul style="list-style-type: none"> - a contraindication for epidural catheter insertion - catheter insertion was impossible - had an allergy to remifentanyl, propofol or ropivacaine - were not fluent in French - suffered from pain in the thoracic region; - declined to participate - age <18 yrs <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>group HR</th> <th>group LR</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>59.6±12.5</td> <td>60.7±14.7</td> </tr> <tr> <td>weight (kg)</td> <td>70.8±15.5</td> <td>70.8±19.7</td> </tr> <tr> <td>height (cm)</td> <td>168.9±7.5</td> <td>167.4±9.6</td> </tr> <tr> <td>sex (m/f)</td> <td>13/7</td> <td>8/10</td> </tr> </tbody> </table> <p>patient flow and follow up:</p> <p>total patient number included:</p> <p>38</p> <p>randomised in:</p> <p>group HR: 20</p> <p>group LR: 18</p> <p>excluded:</p> <p>0</p> <p>analysed:</p> <p>38</p> <p>follow-up:</p> <p><i>Allodynia and acute pain</i></p> <ul style="list-style-type: none"> - every 15 min for 1 h - every h for the next 2 h - every 4 h for the remainder of the initial 24 h postop <p><i>Chronic postop pain</i></p> <p>1, 3, 6 months</p>		group HR	group LR	age (yrs)	59.6±12.5	60.7±14.7	weight (kg)	70.8±15.5	70.8±19.7	height (cm)	168.9±7.5	167.4±9.6	sex (m/f)	13/7	8/10	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - high-dose remifentanyl group (group HR): surgery using a propofol and remifentanyl TCI, CeT of 10 ng/mL - low-dose remifentanyl group (group LR): surgery using TCI, maximal remifentanyl CeT of 2 ng/mL ropivacaine (0.5%) continuously infused through the epidural catheter at rate of 6 mL/h <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - propofol-remifentanyl TCI - TEA for 72h <p>at the end of surgery</p> <p>group HR, at the end of surgery, but before the end of anaesthesia:</p> <p>5 mL bolus 0.5% ropivacaine + 100 µg fentanyl injected into epidural catheter</p> <p>group LR, at the end of surgery, but before the end of anaesthesia:</p> <ul style="list-style-type: none"> - bolus of 100 µg of fentanyl <p>postoperative analgesia:</p> <ul style="list-style-type: none"> - PCA: continuous infusion of a 10 µg/mL fentanyl at 6 mL/h <p>supplementary analgesia</p> <ul style="list-style-type: none"> - if VAS>5 or supplementary analgesia requested: bolus f 2–6 mL 1.5% lidocaine + 6.25 µg/mL epinephrine via epidural catheter - IV paracetamol 1 g/6 h - IV diclofenac 75 mg/12 h - after 72 h (TEA discontinuation): PO morphine given 	<p>postoperative pain [NRS]: mean±SD during hospital stay</p> <table border="1"> <thead> <tr> <th></th> <th>HR</th> <th>LR</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>at rest</td> <td>1.2±1.0</td> <td>1.7±1.6</td> <td>0.64</td> </tr> <tr> <td>at cough</td> <td>2.2±1.3</td> <td>2.6 ±1.7</td> <td>0.77</td> </tr> </tbody> </table> <p>all patients at month 1, month 3 and month 6</p> <table border="1"> <thead> <tr> <th></th> <th>HR</th> <th>LR</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>NRS Max M1</td> <td>4.25±1.92</td> <td>3.75±2.61</td> <td>0.18</td> </tr> <tr> <td>NRS Min M1</td> <td>1.45±1.39</td> <td>1.39±1.46</td> <td>0.89</td> </tr> <tr> <td>NRS at M3</td> <td>2.25±1.86</td> <td>0.94±1.55</td> <td>0.0253</td> </tr> <tr> <td>NRS at M6</td> <td>2.30±1.69</td> <td>0.78±1.80</td> <td>0.003</td> </tr> </tbody> </table> <p>other pain outcomes</p> <p>no. patients with pain (%)</p> <table border="1"> <thead> <tr> <th></th> <th>HR</th> <th>LR</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>M1</td> <td>16 (80%)</td> <td>12 (66.7%)</td> <td>0.364</td> </tr> <tr> <td>M3</td> <td>15 (75%)</td> <td>5 (27.8%)</td> <td>0.013</td> </tr> <tr> <td>M6</td> <td>16 (80%)</td> <td>5 (27.8%)</td> <td>0.008</td> </tr> <tr> <td>Study end</td> <td>14 (70%)</td> <td>3 (16.7%)</td> <td>0.009</td> </tr> </tbody> </table> <p>patients with DN4 neuropathic pain diagnostic questionnaire score >4, n (%)</p> <table border="1"> <thead> <tr> <th></th> <th>HR</th> <th>LR</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>M1</td> <td>16 (80%)</td> <td>5 (27.8%)</td> <td>0.008</td> </tr> <tr> <td>M3</td> <td>10 (50%)</td> <td>3 (16.7%)</td> <td>0.055</td> </tr> <tr> <td>M6</td> <td>11 (55%)</td> <td>3 (16.7%)</td> <td>0.034</td> </tr> <tr> <td>Study end</td> <td>11 (55%)</td> <td>2 (11.1%)</td> <td>0.022</td> </tr> </tbody> </table> <ul style="list-style-type: none"> - patients in the group HR had a higher incidence of analgesic drug use 6 months after hospital discharge - this difference was due essentially to a more frequent use of opioids and amitriptyline <p>surface area of allodynia between groups up to 1 month postop</p> <ul style="list-style-type: none"> - the surface area of allodynia measured with von Frey hairs was much larger in group HR, representing almost three times the surface area larger than group LR (p<0.001) <p>adverse effects/ events</p> <ul style="list-style-type: none"> - not reported 		HR	LR	p	at rest	1.2±1.0	1.7±1.6	0.64	at cough	2.2±1.3	2.6 ±1.7	0.77		HR	LR	p	NRS Max M1	4.25±1.92	3.75±2.61	0.18	NRS Min M1	1.45±1.39	1.39±1.46	0.89	NRS at M3	2.25±1.86	0.94±1.55	0.0253	NRS at M6	2.30±1.69	0.78±1.80	0.003		HR	LR	p	M1	16 (80%)	12 (66.7%)	0.364	M3	15 (75%)	5 (27.8%)	0.013	M6	16 (80%)	5 (27.8%)	0.008	Study end	14 (70%)	3 (16.7%)	0.009		HR	LR	p	M1	16 (80%)	5 (27.8%)	0.008	M3	10 (50%)	3 (16.7%)	0.055	M6	11 (55%)	3 (16.7%)	0.034	Study end	11 (55%)	2 (11.1%)	0.022	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - method used to implement the random allocation sequence no reported - not reported if the sequence was adequately concealed until interventions were assigned - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"High-dose remifentanyl (0.14-0.26 µg/kg/min) without epidural analgesia during surgery is associated with a large area of allodynia around the wound. These patients develop a much higher incidence of chronic pain than those receiving low-dose remifentanyl with epidural analgesia during surgery."</p>
	group HR	group LR																																																																																									
age (yrs)	59.6±12.5	60.7±14.7																																																																																									
weight (kg)	70.8±15.5	70.8±19.7																																																																																									
height (cm)	168.9±7.5	167.4±9.6																																																																																									
sex (m/f)	13/7	8/10																																																																																									
	HR	LR	p																																																																																								
at rest	1.2±1.0	1.7±1.6	0.64																																																																																								
at cough	2.2±1.3	2.6 ±1.7	0.77																																																																																								
	HR	LR	p																																																																																								
NRS Max M1	4.25±1.92	3.75±2.61	0.18																																																																																								
NRS Min M1	1.45±1.39	1.39±1.46	0.89																																																																																								
NRS at M3	2.25±1.86	0.94±1.55	0.0253																																																																																								
NRS at M6	2.30±1.69	0.78±1.80	0.003																																																																																								
	HR	LR	p																																																																																								
M1	16 (80%)	12 (66.7%)	0.364																																																																																								
M3	15 (75%)	5 (27.8%)	0.013																																																																																								
M6	16 (80%)	5 (27.8%)	0.008																																																																																								
Study end	14 (70%)	3 (16.7%)	0.009																																																																																								
	HR	LR	p																																																																																								
M1	16 (80%)	5 (27.8%)	0.008																																																																																								
M3	10 (50%)	3 (16.7%)	0.055																																																																																								
M6	11 (55%)	3 (16.7%)	0.034																																																																																								
Study end	11 (55%)	2 (11.1%)	0.022																																																																																								
<p>Cok et al. 2011</p> <p>Thoracic epidural anaesthesia and analgesia during the perioperative period of thoracic surgery: levobupivacaine versus bupivacaine.</p> <p>J Cardiothorac Vasc Anesth. 2011;25(3):449-54.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age >18 yrs - ASA physical status I–III <p>exclusion criteria</p> <ul style="list-style-type: none"> - uncontrolled hypertension - cardiac valvular diseases - unstable angina pectoris - cardiac, hepatic, or renal failure - contraindications for epidural block <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>group L</th> <th>group B</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		group L	group B	p	age (yrs)				<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group bupivacaine (B): TEA bolus 0.1 mL/kg 0.25% bupivacaine - group levobupivacaine (L): TEA bolus 0.1 mL/kg 0.25% levobupivacaine <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - fentanyl <p>postoperative analgesia</p>	<p>postoperative pain [VAS]:</p> <ul style="list-style-type: none"> - VAS at rest and during activity were comparable between groups for 48 h postop, except for VAS on movement at 36 h postop, which was higher in group L <p>other outcomes</p> <ul style="list-style-type: none"> - total drug consumption, number of demands and boluses during PCA, and rescue analgesic requirements for 48 h postop were similar up to 48 h in the 2 groups (NS) 	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - primary and secondary outcome measures not clearly defined - method used to implement the random allocation sequence not reported - not reported if the sequence was adequately concealed until interventions were assigned - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups 																																																																															
	group L	group B	p																																																																																								
age (yrs)																																																																																											

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																				
	<p>48.32±13.54 44.96±15.58 0.42 weight (kg) 69.12±9.76 0.28±11.43 0.70 height (cm) 168±8.78 166±8.74 0.42 sex (m/f) 22/3 20/5 0.35 ASA (I/II/III) (number of patients) 5/12/8 5/14/6 0.80</p> <p>patient flow and follow up: <u>total patient number included:</u> 50 <u>randomised in:</u> group B: 25 group L: 25 <u>excluded:</u> 0 <u>analysed:</u> 50 <u>follow-up:</u> 30 min, 1, 2, 4, 6, 12, 18, 24, 36, 48 h</p>	<p>- postop PCEA for 48h with the same study drug at 0.125% concentration a 4 mL/h bolus 2 mL/lo 20 min</p> <p>supplemental analgesia</p> <p>- TEA peroperative infusion of the study drug at 0.1 mL/kg/h - IV paracetamol 1 g/8 h - IV tenoxicam 20 mg/8 h <u>if VAS >3: rescue analgesics twice/day</u> - IV fentanyl, 0.3 µg/kg for the first 24 h - PO tramadol 50 mg between 24 and 48 h</p>	<p>- in the first 24 h, none of the patients in group B demanded additional analgesics, whereas 1 patient in group L required fentanyl administration once (NS)</p> <p>- one patient in each group required tramadol in the 24- to 48-h postop period (NS)</p> <p>- the number of dermatomes blocked at each assessment time point (after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, and 20 mins) was similar in both groups</p> <p>adverse events</p> <p>- group L: 1 patient treated for nausea - group B: 2 patients treated for nausea</p>	<p>- flow of participants through each stage not detailed - protocol deviations from study as planned not described</p> <p>level of evidence: 1 authors' conclusion "Thoracic epidural anaesthesia with either levobupivacaine or bupivacaine provided comparable sensory block features, intraoperative hemodynamics, and postoperative analgesia for thoracic surgery"</p>																																																																				
<p>Li et al. 2015 Effects of epidural analgesia with different concentrations of bupivacaine plus fentanyl on pain in patients undergoing thoracic surgery. Int J Clin Exp Med. 2015;8(8):14123-6.</p>	<p>inclusion criteria - not reported exclusion criteria - liver or kidney dysfunction - allergy to any of the study drugs - blood coagulation dysfunction - contraindication for epidural analgesia</p> <p>demographic data:</p> <table border="1"> <thead> <tr> <th>A</th> <th>B</th> <th>C</th> <th>D</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>62.31±8.47</td> <td>63.04±7.82</td> <td>62.63±8.16</td> <td>62.55±7.68</td> </tr> <tr> <td>sex (m/f)</td> <td>17/13</td> <td>15/14</td> <td>17/12</td> <td>16/14</td> </tr> <tr> <td>weight (kg)</td> <td>60.65±5.13</td> <td>59.75±6.62</td> <td>60.48±6.45</td> <td>60.11±6.38</td> </tr> <tr> <td>ASA (I/II)</td> <td>10/20</td> <td>11/18</td> <td>12/18</td> <td>11/19</td> </tr> </tbody> </table> <p>patient flow and follow up: <u>total patient number included:</u> 120 <u>randomised in:</u> group A: 30 group B: 29 group C: 29 group D: 30 <u>excluded:</u> 2 <u>analysed:</u> 118 <u>follow-up:</u> 4, 8, 12, 24, 48 h</p>	A	B	C	D	age (yrs)	62.31±8.47	63.04±7.82	62.63±8.16	62.55±7.68	sex (m/f)	17/13	15/14	17/12	16/14	weight (kg)	60.65±5.13	59.75±6.62	60.48±6.45	60.11±6.38	ASA (I/II)	10/20	11/18	12/18	11/19	<p>intervention prior to anaesthesia PCEA connected after surgery with different doses of bupivacaine + 0.4 µg fentanyl</p> <p>- group A: bupivacaine 0.25% - group B: bupivacaine 0.375% - group C: bupivacaine 0.5% - group D: bupivacaine 0.75%</p> <p>- loading dose: 6 mL, continuous 2 mL/h - PCEA 0.5 mL/ 15 min for 48 h</p> <p>mode of anaesthesia - fentanyl - TEA periop: intermittent injection of 10 mL lidocaine 1%. Discontinued for about 15 m before skin closure.</p> <p>postoperative analgesia PCEA as stated above</p>	<p>postoperative pain [VAS]: mean±SD</p> <table border="1"> <thead> <tr> <th>h</th> <th>4</th> <th>8</th> <th>12*</th> <th>24</th> <th>48</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>1.68±0.70</td> <td>1.16±0.57</td> <td>0.74±0.45</td> <td>0.42±0.31</td> <td>0.22±0.24</td> </tr> <tr> <td>B</td> <td>1.62±0.61</td> <td>1.12±0.56</td> <td>0.68±0.48</td> <td>0.44±0.29</td> <td>0.24±0.27</td> </tr> <tr> <td>C</td> <td>1.52±0.68</td> <td>1.15±0.61</td> <td>0.71±0.46</td> <td>0.41±0.33</td> <td>0.22±0.25</td> </tr> <tr> <td>D</td> <td>1.22±0.62</td> <td>1.08±0.53</td> <td>0.70±0.43</td> <td>0.40±0.30</td> <td>0.21±0.24</td> </tr> <tr> <td>S</td> <td></td> <td>NS</td> <td>NS</td> <td>NS</td> <td>NS</td> </tr> </tbody> </table> <p>- the pressure times of PCA of four groups within 48 h group A group B group C group D 8.25±2.33 5.46±1.32 3.24±0.72 2.11±0.48 S</p> <p>adverse effects/events: n (%)</p> <table border="1"> <thead> <tr> <th>group A</th> <th>group B</th> <th>group C</th> <th>group D</th> </tr> </thead> <tbody> <tr> <td>1(3.3%)</td> <td>2(6.9%)</td> <td>6(20.7%)</td> <td>7(23.3%)</td> </tr> </tbody> </table> <p>- the incidence of respiratory depression in groups C and D were evidently higher than groups A and B; the difference was statistically significant - the gastrointestinal effects, dizziness, pruritus and urinary retention of four groups over the first 48 h were not significantly different.</p>	h	4	8	12*	24	48	A	1.68±0.70	1.16±0.57	0.74±0.45	0.42±0.31	0.22±0.24	B	1.62±0.61	1.12±0.56	0.68±0.48	0.44±0.29	0.24±0.27	C	1.52±0.68	1.15±0.61	0.71±0.46	0.41±0.33	0.22±0.25	D	1.22±0.62	1.08±0.53	0.70±0.43	0.40±0.30	0.21±0.24	S		NS	NS	NS	NS	group A	group B	group C	group D	1(3.3%)	2(6.9%)	6(20.7%)	7(23.3%)	<p>methodological shortcomings - allocation concealment not reported - blinding of outcome assessor not reported - no sample size calculation</p> <p>level of evidence: 1 authors' conclusion "0.25%–0.375% bupivacaine + 0.4 mg fentanyl used in epidural analgesia in patients undergoing thoracic surgery can lead to safe and effective analgesic effect"</p>
A	B	C	D																																																																					
age (yrs)	62.31±8.47	63.04±7.82	62.63±8.16	62.55±7.68																																																																				
sex (m/f)	17/13	15/14	17/12	16/14																																																																				
weight (kg)	60.65±5.13	59.75±6.62	60.48±6.45	60.11±6.38																																																																				
ASA (I/II)	10/20	11/18	12/18	11/19																																																																				
h	4	8	12*	24	48																																																																			
A	1.68±0.70	1.16±0.57	0.74±0.45	0.42±0.31	0.22±0.24																																																																			
B	1.62±0.61	1.12±0.56	0.68±0.48	0.44±0.29	0.24±0.27																																																																			
C	1.52±0.68	1.15±0.61	0.71±0.46	0.41±0.33	0.22±0.25																																																																			
D	1.22±0.62	1.08±0.53	0.70±0.43	0.40±0.30	0.21±0.24																																																																			
S		NS	NS	NS	NS																																																																			
group A	group B	group C	group D																																																																					
1(3.3%)	2(6.9%)	6(20.7%)	7(23.3%)																																																																					
<p>Yang et al. 2015 Pre-emptive epidural analgesia improves post-operative pain and immune function in patients undergoing thoracotomy.</p>	<p>inclusion criteria - stage I (T1-2N0M0) lung cancer - ASA physical status I–III - age 30–70 yrs exclusion criteria - pregnancy</p>	<p>intervention prior to anaesthesia - group control (A): 6 mL saline as a placebo at the corresponding time points, then PCEA - group postoperative TEA (B): 6 mL of 0.125% ropivacaine 30 min after surgery</p>	<p>postoperative pain [VAS]</p> <p><u>at rest</u></p> <table border="1"> <thead> <tr> <th></th> <th>2</th> <th>12</th> <th>24</th> <th>48</th> <th>72 h</th> </tr> </thead> <tbody> <tr> <td>B</td> <td>4.2</td> <td></td> <td>4.5</td> <td></td> <td></td> </tr> <tr> <td>C</td> <td>2.8</td> <td></td> <td>3.3</td> <td></td> <td></td> </tr> </tbody> </table>		2	12	24	48	72 h	B	4.2		4.5			C	2.8		3.3			<p>methodological shortcomings - method used to implement the random allocation sequence not reported - not reported if the sequence was adequately concealed until interventions were assigned</p>																																																		
	2	12	24	48	72 h																																																																			
B	4.2		4.5																																																																					
C	2.8		3.3																																																																					

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																																																				
ANZ J Surg. 2015;85(6):472-7.	<ul style="list-style-type: none"> - hypertension - chronic pain or regular intake of analgesics - drug addiction - body mass index ≥ 24 m/kg² - body temperature disturbance - previous or current treatment with antibiotics - corticosteroid therapy - epidural analgesia contraindications <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>A</th> <th>B</th> <th>C</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>57.5\pm28.3</td> <td>55.5\pm22.6</td> <td>52.5\pm24.5</td> </tr> <tr> <td>sex (m/f)</td> <td>22/18</td> <td>25/15</td> <td>27/13</td> </tr> <tr> <td>weight (kg)</td> <td>62.8\pm10.2</td> <td>67.5\pm8.5</td> <td>64.8\pm10.9</td> </tr> <tr> <td>height (cm)</td> <td>176.5\pm8.2</td> <td>171.5\pm5.5</td> <td>172.5\pm6.8</td> </tr> <tr> <td>smoking history (pack-years)</td> <td>23.5\pm10.2</td> <td>28.5\pm12.5</td> <td>26.7\pm13.8</td> </tr> <tr> <td>ASA (I/II/III)</td> <td>4/33/3</td> <td>6/31/3</td> <td>7/28/5</td> </tr> <tr> <td>TNM stage (I/IIa/IIb)</td> <td>7/15/18</td> <td>6/15/19</td> <td>4/18/18</td> </tr> </tbody> </table> <p>patient flow and follow up: <u>total patient number included:</u> 90 <u>randomised in:</u> group A: 30 group B: 30 group C: 30 <u>excluded:</u> group B: 3 group C: 3 <u>analysed:</u> 84 <u>follow-up:</u> 0, 2, 12, 24, 48, 72 h</p>		A	B	C	age (yrs)	57.5 \pm 28.3	55.5 \pm 22.6	52.5 \pm 24.5	sex (m/f)	22/18	25/15	27/13	weight (kg)	62.8 \pm 10.2	67.5 \pm 8.5	64.8 \pm 10.9	height (cm)	176.5 \pm 8.2	171.5 \pm 5.5	172.5 \pm 6.8	smoking history (pack-years)	23.5 \pm 10.2	28.5 \pm 12.5	26.7 \pm 13.8	ASA (I/II/III)	4/33/3	6/31/3	7/28/5	TNM stage (I/IIa/IIb)	7/15/18	6/15/19	4/18/18	<ul style="list-style-type: none"> - group pre-emptive TEA (C): 6 mL of 0.125% ropivacaine, 30 min before incision, then every 60 min during surgery <p>surgical procedure n</p> <table border="1"> <thead> <tr> <th>Procedure</th> <th>A</th> <th>B</th> <th>C</th> </tr> </thead> <tbody> <tr> <td>Lobectomy</td> <td>20</td> <td>22</td> <td>24</td> </tr> <tr> <td>Pneumonectomy</td> <td>4</td> <td>6</td> <td>8</td> </tr> <tr> <td>Bi-lobectomy</td> <td>6</td> <td>4</td> <td>2</td> </tr> <tr> <td>Wedge resection</td> <td>10</td> <td>8</td> <td>6</td> </tr> <tr> <td>Side (R/L)</td> <td>20/20</td> <td>26/14</td> <td>22/18</td> </tr> </tbody> </table> <p>mode of anaesthesia - fentanyl for induction, then remifentanyl</p> <p>postoperative analgesia - PCEA for 72 h: 1mL bolus 0.125% ropivacaine, continuous infusion of 2 mL/h, to 15 min, to a max of 15 mL in 4h</p> <p>supplemental analgesia - if VAS >4: - bolus IV tramadol 100 mg - IM morphine 5 mg if required</p>	Procedure	A	B	C	Lobectomy	20	22	24	Pneumonectomy	4	6	8	Bi-lobectomy	6	4	2	Wedge resection	10	8	6	Side (R/L)	20/20	26/14	22/18	<table border="1"> <thead> <tr> <th></th> <th>S</th> <th>NS</th> <th>S</th> <th>NS</th> <th>NS</th> </tr> </thead> <tbody> <tr> <td><u>on coughing</u></td> <td>2</td> <td>12</td> <td>24</td> <td>48</td> <td>72 h</td> </tr> <tr> <td>B</td> <td>4.2</td> <td>4.6</td> <td>4.5</td> <td>3.9</td> <td></td> </tr> <tr> <td>C</td> <td>2.8</td> <td>3.7</td> <td>3.3</td> <td>3.1</td> <td></td> </tr> <tr> <td></td> <td>S</td> <td>S</td> <td>S</td> <td>S</td> <td>NS</td> </tr> </tbody> </table> <ul style="list-style-type: none"> - there were significantly lower postop VAS scores at rest and during coughing in groups B and C compared with group A - from 2 h to 48 h postop, VAS scores of group C were always lower than group B at rest and coughing (but not always S, see graph) - PCEA demands were significantly lower at 24, 48 and 72 h in groups B and C compared with group A - PCEA demands were significantly less in group B vs group C at: 24 h (83 vs 108 mL) 48 h (135 vs 167 mL) 72 h (179 vs 209 mL) - the % of patients who required rescue analgesics were higher in group A compared with groups B and C. <table border="1"> <thead> <tr> <th></th> <th>A</th> <th>B</th> <th>C</th> <th>S</th> </tr> </thead> <tbody> <tr> <td>adverse effects/ events n (%):</td> <td>60.0%</td> <td>22.2%</td> <td>14.8%</td> <td></td> </tr> </tbody> </table> <p>*=significant vs group A; **=significant vs group B</p> <table border="1"> <thead> <tr> <th></th> <th>A</th> <th>B</th> <th>C</th> </tr> </thead> <tbody> <tr> <td>nausea/vomiting</td> <td>24 (80.0)</td> <td>11 (40.7)*</td> <td>4 (14.8)**</td> </tr> <tr> <td>pruritis</td> <td>9 (30.0)</td> <td>2 (7.4)*</td> <td>2 (7.4)*</td> </tr> <tr> <td>hypotension</td> <td>23 (76.7)</td> <td>11 (40.7)*</td> <td>4 (14.8)**</td> </tr> <tr> <td>respiratory depression</td> <td>7 (20.0)</td> <td>1 (3.7)*</td> <td>0*</td> </tr> </tbody> </table> <p>additional outcomes - expression of proteins TNF-α, IL-8 and IL-6 were lower at 24, 48 and 72 h postop in groups B and C compared with group A (p<0.05).</p>		S	NS	S	NS	NS	<u>on coughing</u>	2	12	24	48	72 h	B	4.2	4.6	4.5	3.9		C	2.8	3.7	3.3	3.1			S	S	S	S	NS		A	B	C	S	adverse effects/ events n (%):	60.0%	22.2%	14.8%			A	B	C	nausea/vomiting	24 (80.0)	11 (40.7)*	4 (14.8)**	pruritis	9 (30.0)	2 (7.4)*	2 (7.4)*	hypotension	23 (76.7)	11 (40.7)*	4 (14.8)**	respiratory depression	7 (20.0)	1 (3.7)*	0*	<ul style="list-style-type: none"> - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion "Lower VAS scores at rest and on coughing in group C compared with group B, less boluses of PCEA at 24, 48 and 72 h after surgery"</p>
	A	B	C																																																																																																																					
age (yrs)	57.5 \pm 28.3	55.5 \pm 22.6	52.5 \pm 24.5																																																																																																																					
sex (m/f)	22/18	25/15	27/13																																																																																																																					
weight (kg)	62.8 \pm 10.2	67.5 \pm 8.5	64.8 \pm 10.9																																																																																																																					
height (cm)	176.5 \pm 8.2	171.5 \pm 5.5	172.5 \pm 6.8																																																																																																																					
smoking history (pack-years)	23.5 \pm 10.2	28.5 \pm 12.5	26.7 \pm 13.8																																																																																																																					
ASA (I/II/III)	4/33/3	6/31/3	7/28/5																																																																																																																					
TNM stage (I/IIa/IIb)	7/15/18	6/15/19	4/18/18																																																																																																																					
Procedure	A	B	C																																																																																																																					
Lobectomy	20	22	24																																																																																																																					
Pneumonectomy	4	6	8																																																																																																																					
Bi-lobectomy	6	4	2																																																																																																																					
Wedge resection	10	8	6																																																																																																																					
Side (R/L)	20/20	26/14	22/18																																																																																																																					
	S	NS	S	NS	NS																																																																																																																			
<u>on coughing</u>	2	12	24	48	72 h																																																																																																																			
B	4.2	4.6	4.5	3.9																																																																																																																				
C	2.8	3.7	3.3	3.1																																																																																																																				
	S	S	S	S	NS																																																																																																																			
	A	B	C	S																																																																																																																				
adverse effects/ events n (%):	60.0%	22.2%	14.8%																																																																																																																					
	A	B	C																																																																																																																					
nausea/vomiting	24 (80.0)	11 (40.7)*	4 (14.8)**																																																																																																																					
pruritis	9 (30.0)	2 (7.4)*	2 (7.4)*																																																																																																																					
hypotension	23 (76.7)	11 (40.7)*	4 (14.8)**																																																																																																																					
respiratory depression	7 (20.0)	1 (3.7)*	0*																																																																																																																					
<p>Tekelioğlu et al. 2012 Combinations of fentanyl and levobupivacaine for post-thoracotomy pain. Acta Anaesthesiol Taiwan. 2012;50(3):131-3.</p>	<p>inclusion criteria - age 20–80 yrs - ASA physical status I–III</p> <p>exclusion criteria - allergies to any of the study medicines - serious cardiac, renal, or liver diseases - morbid obesity (body mass index >40) - history of bleeding disorders - contraindications for epidural anaesthesia</p>	<p>mode of anaesthesia - not reported</p> <p>at the end of surgery - PCEA: loading dose of 14 mL at an infusion rate of 4 mL/h + bolus dose of 2 mL/h, with 15 min lo, to max 60 mL in 4-hr</p> <p>supplemental analgesia - if VAS >3, rescue IM pethidine 1 mg/kg</p>	<p>postoperative pain [VAS]: mean\pmSD</p> <p>VAS I (at rest)</p> <table border="1"> <thead> <tr> <th></th> <th>Group I</th> <th>Group II</th> <th>Group III</th> </tr> </thead> <tbody> <tr> <td>5 min</td> <td>1.75\pm0.97</td> <td>3.60\pm1.10</td> <td>4.25\pm0.91</td> </tr> <tr> <td>15 min</td> <td>1.60\pm0.75</td> <td>2.55\pm1.05</td> <td>2.90\pm0.91</td> </tr> <tr> <td>30 min</td> <td>1.10\pm0.79</td> <td>1.95\pm0.69</td> <td>2.35\pm 0.99</td> </tr> <tr> <td>1 h</td> <td>0.50\pm0.51</td> <td>1.40\pm0.82</td> <td>2.45\pm 1.1</td> </tr> <tr> <td>2 h</td> <td>0.40\pm0.50</td> <td>1.15\pm1.04</td> <td>1.95\pm 0.95</td> </tr> <tr> <td>8 h</td> <td>0.10\pm0.31</td> <td>0.45\pm0.68</td> <td>1.40\pm1.39</td> </tr> <tr> <td>24 h</td> <td>0.05\pm0.22</td> <td>0.1\pm0.31</td> <td>0.55\pm0.69</td> </tr> </tbody> </table>		Group I	Group II	Group III	5 min	1.75 \pm 0.97	3.60 \pm 1.10	4.25 \pm 0.91	15 min	1.60 \pm 0.75	2.55 \pm 1.05	2.90 \pm 0.91	30 min	1.10 \pm 0.79	1.95 \pm 0.69	2.35 \pm 0.99	1 h	0.50 \pm 0.51	1.40 \pm 0.82	2.45 \pm 1.1	2 h	0.40 \pm 0.50	1.15 \pm 1.04	1.95 \pm 0.95	8 h	0.10 \pm 0.31	0.45 \pm 0.68	1.40 \pm 1.39	24 h	0.05 \pm 0.22	0.1 \pm 0.31	0.55 \pm 0.69	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - primary and secondary outcome measures not defined - not reported how sample size was determined and explanation of any interim analyses and/or stopping rules - method used to implement the random allocation sequence not reported - not reported whether the sequence was adequately concealed until interventions were assigned 																																																																																				
	Group I	Group II	Group III																																																																																																																					
5 min	1.75 \pm 0.97	3.60 \pm 1.10	4.25 \pm 0.91																																																																																																																					
15 min	1.60 \pm 0.75	2.55 \pm 1.05	2.90 \pm 0.91																																																																																																																					
30 min	1.10 \pm 0.79	1.95 \pm 0.69	2.35 \pm 0.99																																																																																																																					
1 h	0.50 \pm 0.51	1.40 \pm 0.82	2.45 \pm 1.1																																																																																																																					
2 h	0.40 \pm 0.50	1.15 \pm 1.04	1.95 \pm 0.95																																																																																																																					
8 h	0.10 \pm 0.31	0.45 \pm 0.68	1.40 \pm 1.39																																																																																																																					
24 h	0.05 \pm 0.22	0.1 \pm 0.31	0.55 \pm 0.69																																																																																																																					

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																														
	<p>demographic data:</p> <table border="1"> <thead> <tr> <th>group I</th> <th>group II</th> <th>group III</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>sex (m/f)</td> <td>17/3</td> <td>16/4</td> <td>17/3</td> <td>0.376</td> </tr> <tr> <td>age (yrs)</td> <td>51.35±11.96</td> <td>44.80±17.24</td> <td>46.15±16.21</td> <td>0.367</td> </tr> <tr> <td>ASA (I/II/III)</td> <td>0/13/7</td> <td>0/12/8</td> <td>1/14/5</td> <td>0.089</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 60 <u>randomised in:</u> group I: 20 group II: 20 group III: 20 <u>excluded:</u> not reported <u>analysed:</u> 60 <u>follow-up:</u> 5, 15, 30 mins, 1, 2, 8, 24 h</p>	group I	group II	group III	p	sex (m/f)	17/3	16/4	17/3	0.376	age (yrs)	51.35±11.96	44.80±17.24	46.15±16.21	0.367	ASA (I/II/III)	0/13/7	0/12/8	1/14/5	0.089	<p>postoperative analgesia</p> <ul style="list-style-type: none"> - group I: 0.125% levobupivacaine + 3 µg/mL fentanyl - group II: 0.1% levobupivacaine + 3 µg/mL fentanyl - group III: 0.05% levobupivacaine + 3 µg/mL fentanyl 	<p>All p<0.001</p> <p>VAS II (deep breathing or coughing)</p> <table border="1"> <thead> <tr> <th>Time</th> <th>Group I</th> <th>Group II</th> <th>Group III</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>5 min</td> <td>2.80 ± 1.40</td> <td>5.05 ± 1.32</td> <td>6.45 ± 1.19</td> <td></td> </tr> <tr> <td>15 min</td> <td>2.55 ± 0.89</td> <td>3.95 ± 0.95</td> <td>4.25 ± 1.16</td> <td></td> </tr> <tr> <td>30 min</td> <td>2.25 ± 0.91</td> <td>3.0 ± 0.86</td> <td>4.20 ± 1.24</td> <td></td> </tr> <tr> <td>1 h</td> <td>1.50 ± 0.69</td> <td>2.45 ± 0.83</td> <td>4.35 ± 1.27</td> <td></td> </tr> <tr> <td>2 h</td> <td>1.35 ± 0.75</td> <td>2.0 ± 0.92</td> <td>3.55 ± 0.95</td> <td></td> </tr> <tr> <td>8 h</td> <td>0.60 ± 0.60</td> <td>1.1 ± 0.72</td> <td>3.05 ± 1.39</td> <td></td> </tr> <tr> <td>24 h</td> <td>0.50</td> <td>0.61</td> <td>0.75</td> <td>0.64</td> </tr> <tr> <td></td> <td>2.15</td> <td>1.04</td> <td>< 0.001</td> <td></td> </tr> </tbody> </table> <p>All p<0.001</p> <p>other outcomes</p> <table border="1"> <thead> <tr> <th></th> <th>group I</th> <th>group II</th> <th>group III</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>MAP</td> <td>85.45±12.03</td> <td>85.8±10.62</td> <td>93.55±9.53</td> <td>0.033</td> </tr> <tr> <td>HRa</td> <td>85.5±11.38</td> <td>88.7±15.15</td> <td>97.55±14.84</td> <td>0.023</td> </tr> <tr> <td>RR</td> <td>20.1±6.4</td> <td>19.1±3.43</td> <td>22.2±4.38</td> <td>0.134</td> </tr> <tr> <td>SpO2</td> <td>98.8±1.15</td> <td>98.55±1.05</td> <td>98±1.77</td> <td>0.175</td> </tr> <tr> <td>PSS</td> <td>1.15±0.37</td> <td>1.45±0.68</td> <td>2.1±0.71</td> <td><0.001</td> </tr> </tbody> </table> <p>- Bromage scale was 3 in all groups, and no motor blocks were observed</p>	Time	Group I	Group II	Group III	p	5 min	2.80 ± 1.40	5.05 ± 1.32	6.45 ± 1.19		15 min	2.55 ± 0.89	3.95 ± 0.95	4.25 ± 1.16		30 min	2.25 ± 0.91	3.0 ± 0.86	4.20 ± 1.24		1 h	1.50 ± 0.69	2.45 ± 0.83	4.35 ± 1.27		2 h	1.35 ± 0.75	2.0 ± 0.92	3.55 ± 0.95		8 h	0.60 ± 0.60	1.1 ± 0.72	3.05 ± 1.39		24 h	0.50	0.61	0.75	0.64		2.15	1.04	< 0.001			group I	group II	group III	p	MAP	85.45±12.03	85.8±10.62	93.55±9.53	0.033	HRa	85.5±11.38	88.7±15.15	97.55±14.84	0.023	RR	20.1±6.4	19.1±3.43	22.2±4.38	0.134	SpO2	98.8±1.15	98.55±1.05	98±1.77	0.175	PSS	1.15±0.37	1.45±0.68	2.1±0.71	<0.001	<p>- not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups</p> <p>- flow of participants through each stage not described</p> <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"the use of 0.125% levobupivacaine, together with 3 mg/mL fentanyl, constitutes a good combination, and can be used safely without causing hemodynamic change and motor block."</p>
group I	group II	group III	p																																																																																															
sex (m/f)	17/3	16/4	17/3	0.376																																																																																														
age (yrs)	51.35±11.96	44.80±17.24	46.15±16.21	0.367																																																																																														
ASA (I/II/III)	0/13/7	0/12/8	1/14/5	0.089																																																																																														
Time	Group I	Group II	Group III	p																																																																																														
5 min	2.80 ± 1.40	5.05 ± 1.32	6.45 ± 1.19																																																																																															
15 min	2.55 ± 0.89	3.95 ± 0.95	4.25 ± 1.16																																																																																															
30 min	2.25 ± 0.91	3.0 ± 0.86	4.20 ± 1.24																																																																																															
1 h	1.50 ± 0.69	2.45 ± 0.83	4.35 ± 1.27																																																																																															
2 h	1.35 ± 0.75	2.0 ± 0.92	3.55 ± 0.95																																																																																															
8 h	0.60 ± 0.60	1.1 ± 0.72	3.05 ± 1.39																																																																																															
24 h	0.50	0.61	0.75	0.64																																																																																														
	2.15	1.04	< 0.001																																																																																															
	group I	group II	group III	p																																																																																														
MAP	85.45±12.03	85.8±10.62	93.55±9.53	0.033																																																																																														
HRa	85.5±11.38	88.7±15.15	97.55±14.84	0.023																																																																																														
RR	20.1±6.4	19.1±3.43	22.2±4.38	0.134																																																																																														
SpO2	98.8±1.15	98.55±1.05	98±1.77	0.175																																																																																														
PSS	1.15±0.37	1.45±0.68	2.1±0.71	<0.001																																																																																														
<p>Ali et al. 2010</p> <p>Prospective, randomized, controlled trial of thoracic epidural or patient-controlled opiate analgesia on perioperative quality of life. Br J Anaesth. 2010;104(3):292-7.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age 18–80 yrs <p>exclusion criteria</p> <ul style="list-style-type: none"> - age <18 or >80 yrs - patients with educational or physical disability, - severe cardiovascular disease - severe respiratory disease (forced expiratory volume 50% of predicted) - contraindication to epidural catheter placement <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>TEA</th> <th>PCA</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>58 (20–80)</td> <td>58 (20–80)</td> </tr> <tr> <td>sex (m/f)</td> <td>18/19</td> <td>17/6</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 68 <u>randomised in:</u> group TEA: 38 group PCA: 30 <u>excluded:</u> group TEA: 1 group PCA: 7 <u>analysed:</u> group TEA: 37 group PCA: 23 <u>follow-up:</u> 6, 12, 18 h, 2, 3 days</p>		TEA	PCA	age (yrs)	58 (20–80)	58 (20–80)	sex (m/f)	18/19	17/6	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - not reported <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - not reported <p>surgical approach (n)</p> <table border="1"> <thead> <tr> <th></th> <th>TEA</th> <th>PCA</th> </tr> </thead> <tbody> <tr> <td>Thoracotomy</td> <td>25</td> <td>18</td> </tr> <tr> <td>Oesophagectomy</td> <td>9</td> <td>1</td> </tr> <tr> <td>Laparotomy</td> <td>3</td> <td>4</td> </tr> </tbody> </table> <p>supplemental analgesia</p> <ul style="list-style-type: none"> - not reported <p>postoperative analgesia</p> <ul style="list-style-type: none"> - group TEA: 0.1 % bupivacaine + 2 µg/mL fentanyl at 5–10 mL/h - group PCA: PCA, morphine 1 mg/mL, 7 min lo 		TEA	PCA	Thoracotomy	25	18	Oesophagectomy	9	1	Laparotomy	3	4	<p>postoperative pain [VAS]: mean (95% CI)</p> <table border="1"> <thead> <tr> <th>h</th> <th>TEA</th> <th>PCA</th> </tr> </thead> <tbody> <tr> <td>6</td> <td>4.4 (5.3)</td> <td>5.4 (6.6)</td> </tr> <tr> <td>12</td> <td>2.4 (3.0)</td> <td>3.8 (4.8)</td> </tr> <tr> <td>18</td> <td>1.7 (2.4)</td> <td>3.2 (4.4)</td> </tr> <tr> <td>48</td> <td>1.8 (2.2)</td> <td>3.1 (3.9)</td> </tr> <tr> <td>72</td> <td>1.4 (1.9)</td> <td>2.8 (3.8)</td> </tr> </tbody> </table> <p>- p-values at 6, 12, 18 h, and for days 1, 2, and 3 were 0.176, 0.026, 0.018, 0.004, 0.003, and 0.008, respectively</p> <p>- average pain scores were lower in the epidural group at 6, 12, and 18 h and second and third postoperative days in group TEA</p> <p>patient satisfaction</p> <ul style="list-style-type: none"> - overall, patient satisfaction was 97.3% in the epidural group TEA compared with 74% in the group PCA (p<0.05) - patient satisfaction: one patient in the epidural group was not satisfied with the mode of analgesia (due to catheter leakage) 	h	TEA	PCA	6	4.4 (5.3)	5.4 (6.6)	12	2.4 (3.0)	3.8 (4.8)	18	1.7 (2.4)	3.2 (4.4)	48	1.8 (2.2)	3.1 (3.9)	72	1.4 (1.9)	2.8 (3.8)	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - failure of the block randomisation to achieve equal numbers of patients in the two groups - not reported whether the sequence was adequately concealed until interventions were assigned - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups - not reported if participants, those administering the interventions, and those assessing the outcomes were aware of group assignment - dates defining the period of recruitment and follow-up not reported - all important adverse events or side-effects in each intervention group were not reported <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"Epidural analgesia with local anaesthetic and opioid improves QoL and delivers better analgesia compared with PCA in patients undergoing major thoraco-abdominal surgery."</p>																																																							
	TEA	PCA																																																																																																
age (yrs)	58 (20–80)	58 (20–80)																																																																																																
sex (m/f)	18/19	17/6																																																																																																
	TEA	PCA																																																																																																
Thoracotomy	25	18																																																																																																
Oesophagectomy	9	1																																																																																																
Laparotomy	3	4																																																																																																
h	TEA	PCA																																																																																																
6	4.4 (5.3)	5.4 (6.6)																																																																																																
12	2.4 (3.0)	3.8 (4.8)																																																																																																
18	1.7 (2.4)	3.2 (4.4)																																																																																																
48	1.8 (2.2)	3.1 (3.9)																																																																																																
72	1.4 (1.9)	2.8 (3.8)																																																																																																
<p>Sagiroglu et al. 2014</p> <p>A comparison of thoracic or lumbar patient-controlled epidural analgesia methods after thoracic surgery.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age 46–86 yrs - ASA physical status I–III <p>exclusion criteria</p> <ul style="list-style-type: none"> - ASA physical status >III 	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group TEA: T4-T6 - group LEA: L2-L3 - 0.125% bupivacaine with 0.6 µg/mL sufentanil 	<p>postoperative pain [VAS]: mean±SD</p> <table border="1"> <thead> <tr> <th>at rest</th> <th>TEA</th> <th>LEA</th> </tr> </thead> <tbody> <tr> <td>Basal</td> <td>5.43±1.8</td> <td>5.36±1.85</td> </tr> <tr> <td>2</td> <td>4.28±1.59</td> <td>5.33±1.88</td> </tr> </tbody> </table>	at rest	TEA	LEA	Basal	5.43±1.8	5.36±1.85	2	4.28±1.59	5.33±1.88	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - method used to implement the random allocation sequence not reported - not reported if the sequence was adequately concealed until interventions were assigned 																																																																																					
at rest	TEA	LEA																																																																																																
Basal	5.43±1.8	5.36±1.85																																																																																																
2	4.28±1.59	5.33±1.88																																																																																																

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																																																										
World J Surg Oncol. 2014;12:96.	<ul style="list-style-type: none"> - known drug allergies - prior lumbar spine surgery - pregnancy - abnormal coagulation tests - history of comorbidities - neurological impairment causing inability to understand consent form or pain measurement <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>TEA</th> <th>LEA</th> <th>*P</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>55.37±13.3</td> <td>52.73±13.33</td> <td>0.281</td> </tr> <tr> <td>height (cm)</td> <td>167.77±7.87</td> <td>166.4±10.705</td> <td>0.428</td> </tr> <tr> <td>weight (kg)</td> <td>69.39±12.44</td> <td>74.24±15.83</td> <td>0.066</td> </tr> <tr> <td>BMI (kg/m²)</td> <td>24.6±3.58</td> <td>25.14±4.9</td> <td>0.492</td> </tr> <tr> <td>sex</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- female</td> <td>7 (12.3)</td> <td>9 (14.3)</td> <td>0.747</td> </tr> <tr> <td>- male</td> <td>50 (87.7)</td> <td>54 (85.7)</td> <td></td> </tr> <tr> <td>ASA status</td> <td></td> <td></td> <td></td> </tr> <tr> <td>I</td> <td>6 (10.5)</td> <td>10 (15.9)</td> <td>0.39</td> </tr> <tr> <td>II</td> <td>40 (70.2)</td> <td>36 (57.1)</td> <td>0.139</td> </tr> <tr> <td>III</td> <td>11 (19.3)</td> <td>17 (27)</td> <td>0.32</td> </tr> <tr> <td>Charlson comorbidity index</td> <td></td> <td></td> <td></td> </tr> <tr> <td>0</td> <td>6 (10.5)</td> <td>9 (14.3)</td> <td>0.534</td> </tr> <tr> <td>1-2</td> <td>38 (66.7)</td> <td>40 (63.5)</td> <td>0.716</td> </tr> <tr> <td>>2</td> <td>13 (22.8)</td> <td>14 (22.2)</td> <td>0.939</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 134 <u>randomised in:</u> group TEA: 65 group LEA: 69 <u>excluded:</u> group TEA: 7 group LEA: 5 <u>analysed:</u> group TEA: 57 group LEA: 63 <u>follow-up:</u> 0, 2, 4, 8, 16, 24 h</p>		TEA	LEA	*P	age (yrs)	55.37±13.3	52.73±13.33	0.281	height (cm)	167.77±7.87	166.4±10.705	0.428	weight (kg)	69.39±12.44	74.24±15.83	0.066	BMI (kg/m ²)	24.6±3.58	25.14±4.9	0.492	sex				- female	7 (12.3)	9 (14.3)	0.747	- male	50 (87.7)	54 (85.7)		ASA status				I	6 (10.5)	10 (15.9)	0.39	II	40 (70.2)	36 (57.1)	0.139	III	11 (19.3)	17 (27)	0.32	Charlson comorbidity index				0	6 (10.5)	9 (14.3)	0.534	1-2	38 (66.7)	40 (63.5)	0.716	>2	13 (22.8)	14 (22.2)	0.939	<ul style="list-style-type: none"> - infusion of 2 mL/h intraop <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - fentanyl - intraoperative TEA or LEA <p>postoperative analgesia</p> <ul style="list-style-type: none"> - PCEA: 0.1 mL/kg/h, 2 mL bolus, lo 30 min for 24 h <p>additional analgesia</p> <ul style="list-style-type: none"> - IV paracetamol 1 g/8 h - if VAS score >3 after 4 boluses, IV morphine 2 mg 	<table border="1"> <tbody> <tr> <td>4</td> <td>3.84±1.84</td> <td>4.84±2.3</td> </tr> <tr> <td>8</td> <td>1.86±1.97</td> <td>2.84±2.02</td> </tr> <tr> <td>16</td> <td>1.72±1.81</td> <td>2.49±2.17</td> </tr> <tr> <td>24</td> <td>1.51±1.72</td> <td>1.6±1.77</td> </tr> </tbody> </table> <p>after cough</p> <table border="1"> <tbody> <tr> <td>Basal</td> <td>7.75±1.48</td> <td>7.32±1.52</td> </tr> <tr> <td>2</td> <td>5.23±1.96</td> <td>6.02±2.07</td> </tr> <tr> <td>4</td> <td>4.72±2.47</td> <td>5.81±2.7</td> </tr> <tr> <td>8</td> <td>3.18±0.66</td> <td>4.1±2.09</td> </tr> <tr> <td>16</td> <td>3.54±1.72</td> <td>4.03±1.78</td> </tr> <tr> <td>24</td> <td>3.21±1.7</td> <td>3.81±2.01</td> </tr> </tbody> </table> <p>total dosage of morphine [mg]: mean±SD</p> <ul style="list-style-type: none"> - total 24-h analgesic consumption was different between groups (175±20 mL versus 185±31 mL; p=0.034), - total morphine consumption was similar (8.2±11.3 mg versus 10.3±11 mg) <p>adverse effects/ events: n (%)</p> <table border="1"> <thead> <tr> <th></th> <th>TEA</th> <th>LEA</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>nausea and vomiting</td> <td>7 (11.1)</td> <td>4 (7)</td> <td>0.438</td> </tr> <tr> <td>hypotension episode</td> <td>8 (12.7)</td> <td>21 (36.8)</td> <td>0.002*</td> </tr> <tr> <td>bradycardia</td> <td>2 (3.2)</td> <td>9 (15.8)</td> <td>0.017*</td> </tr> <tr> <td>ICU stay >24 h</td> <td>0 (0)</td> <td>5 (7.9)</td> <td>0.031*</td> </tr> <tr> <td>atelectasis</td> <td>1 (1.8)</td> <td>7 (11.1)</td> <td>0.042*</td> </tr> <tr> <td>pneumonia</td> <td>2 (3.2)</td> <td>3 (5.3)</td> <td>0.567</td> </tr> </tbody> </table>	4	3.84±1.84	4.84±2.3	8	1.86±1.97	2.84±2.02	16	1.72±1.81	2.49±2.17	24	1.51±1.72	1.6±1.77	Basal	7.75±1.48	7.32±1.52	2	5.23±1.96	6.02±2.07	4	4.72±2.47	5.81±2.7	8	3.18±0.66	4.1±2.09	16	3.54±1.72	4.03±1.78	24	3.21±1.7	3.81±2.01		TEA	LEA	p	nausea and vomiting	7 (11.1)	4 (7)	0.438	hypotension episode	8 (12.7)	21 (36.8)	0.002*	bradycardia	2 (3.2)	9 (15.8)	0.017*	ICU stay >24 h	0 (0)	5 (7.9)	0.031*	atelectasis	1 (1.8)	7 (11.1)	0.042*	pneumonia	2 (3.2)	3 (5.3)	0.567	<ul style="list-style-type: none"> - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups - dates defining the period of recruitment and follow-up not reported <p>level of evidence: 1 authors' conclusion "TEA has beneficial haemodynamic effects in comparison to LEA after thoracotomy, along with a more satisfactory pain relief profile in the 24-hour postoperative period"</p>
	TEA	LEA	*P																																																																																																																											
age (yrs)	55.37±13.3	52.73±13.33	0.281																																																																																																																											
height (cm)	167.77±7.87	166.4±10.705	0.428																																																																																																																											
weight (kg)	69.39±12.44	74.24±15.83	0.066																																																																																																																											
BMI (kg/m ²)	24.6±3.58	25.14±4.9	0.492																																																																																																																											
sex																																																																																																																														
- female	7 (12.3)	9 (14.3)	0.747																																																																																																																											
- male	50 (87.7)	54 (85.7)																																																																																																																												
ASA status																																																																																																																														
I	6 (10.5)	10 (15.9)	0.39																																																																																																																											
II	40 (70.2)	36 (57.1)	0.139																																																																																																																											
III	11 (19.3)	17 (27)	0.32																																																																																																																											
Charlson comorbidity index																																																																																																																														
0	6 (10.5)	9 (14.3)	0.534																																																																																																																											
1-2	38 (66.7)	40 (63.5)	0.716																																																																																																																											
>2	13 (22.8)	14 (22.2)	0.939																																																																																																																											
4	3.84±1.84	4.84±2.3																																																																																																																												
8	1.86±1.97	2.84±2.02																																																																																																																												
16	1.72±1.81	2.49±2.17																																																																																																																												
24	1.51±1.72	1.6±1.77																																																																																																																												
Basal	7.75±1.48	7.32±1.52																																																																																																																												
2	5.23±1.96	6.02±2.07																																																																																																																												
4	4.72±2.47	5.81±2.7																																																																																																																												
8	3.18±0.66	4.1±2.09																																																																																																																												
16	3.54±1.72	4.03±1.78																																																																																																																												
24	3.21±1.7	3.81±2.01																																																																																																																												
	TEA	LEA	p																																																																																																																											
nausea and vomiting	7 (11.1)	4 (7)	0.438																																																																																																																											
hypotension episode	8 (12.7)	21 (36.8)	0.002*																																																																																																																											
bradycardia	2 (3.2)	9 (15.8)	0.017*																																																																																																																											
ICU stay >24 h	0 (0)	5 (7.9)	0.031*																																																																																																																											
atelectasis	1 (1.8)	7 (11.1)	0.042*																																																																																																																											
pneumonia	2 (3.2)	3 (5.3)	0.567																																																																																																																											